Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GRB2
REST API REST API
Homo sapiens
GRB2 is differentially expressed in 255 experiments: 93 organism parts: pancreas, spleen, ... (91 more);, 164 disease states: normal, control, ... (162 more);, 65 cell types 311 cell lines 30 compound treatments and 67 other conditions.
Synonyms NCKAP2
Orthologs GRB2 (2 of 2) (Danio rerio)   grb2 (Danio rerio)   Q3T0F9_BOVIN (Bos taurus)   Grb2 (Rattus norvegicus)   ENSCING00000005670 (Ciona intestinalis)   Grb2 (Mus musculus)   A3R0S3_CHICK (Gallus gallus)   drk (Drosophila melanogaster)   grb2 (Xenopus laevis)   GRB2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, vesicle membrane, negative regulation of epidermal growth factor receptor signaling pathway, protein binding, cytoplasm, epidermal growth factor receptor signaling pathway, protein complex, membrane, Golgi apparatus, insulin receptor signaling pathway, insulin receptor substrate binding, cell-cell signaling, blood coagulation, protein domain specific binding, receptor internalization, ephrin receptor binding, epidermal growth factor receptor binding, fibroblast growth factor receptor signaling pathway, cell differentiation, regulation of MAPKKK cascade, Ras protein signal transduction, axon guidance, aging, SH3/SH2 adaptor activity, phosphoprotein binding, leukocyte migration, branching involved in embryonic placenta morphogenesis, anatomical structure formation involved in morphogenesis, phosphotyrosine binding, interspecies interaction between organisms, nerve growth factor receptor signaling pathway, T cell costimulation, protein heterooligomerization, positive regulation of reactive oxygen species metabolic process, signal transduction in response to DNA damage, cellular response to ionizing radiation, cell junction assembly
InterPro Term SH2, SH3_domain, SH3_2, p67phox, SH3_3
UniProt Accession P62993, B0LPF3
Search EB-eye ENSG00000177885
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-MTAB-62, ... (27 experiments)

Factor Value U/D Experiments
HL-60
2
E-MTAB-37, E-GEOD-24147
MCF-7
2
E-GEOD-3529, E-GEOD-20081
MDA468
2
E-MEXP-440, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
HeLa cells (Luciferase siRNA transfection)
1
E-MTAB-62
RPMI 8226
1
E-MEXP-921
305 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, ... (34 experiments)

Factor Value U/D Experiments
CD14+ monocyte
1
2
E-AFMX-5, E-TABM-145
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
CD326negCD56+ cell
1
E-GEOD-21668
HLA-DR positive T-cell
1
E-GEOD-6338
neuroblastoma cell
1
E-MEXP-669
59 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-16363, E-MTAB-680, ... (53 experiments)

Factor Value U/D Experiments
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
prostate carcinoma
2
E-MEXP-2034, E-GEOD-96
dermatomyositis
1
E-MTAB-62
Crohn's disease
1
E-GEOD-3365
158 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (22 experiments)

Factor Value U/D Experiments
none
3
6
E-TABM-782, E-GEOD-2803, E-GEOD-412, E-GEOD-5824, E-MEXP-1958, ... (9 experiments)
BCR/FGFR1
1
E-GEOD-15811
Cxcl12
1
E-GEOD-7307
granulocyte-colony stimulating factor
1
E-GEOD-7400
hydroxyurea
1
E-GEOD-6431
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
24 more value(s).


Biopsy tissue

studied in E-GEOD-5851

Factor Value U/D Experiments
lung
1
E-GEOD-5851


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-20499, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-TABM-147

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-4025, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-GEOD-6431, ... (7 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-2466, E-MEXP-421, E-GEOD-22593, E-GEOD-2292, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-6432, E-GEOD-5681, E-MEXP-2657, E-GEOD-12773, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (31 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.26 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM